Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Macdonald, D. R.
Right arrow Articles by Cairncross, J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Macdonald, D. R.
Right arrow Articles by Cairncross, J. G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Journal of Clinical Oncology, Vol 8, 1277-1280, Copyright © 1990 by American Society of Clinical Oncology

ARTICLES

Response criteria for phase II studies of supratentorial malignant glioma

DR Macdonald, TL Cascino, SC Schold Jr and JG Cairncross
Department of Clinical Neurological Sciences, Western Ontario, London, Canada.

We suggest "new" response criteria for phase II studies of supratentorial malignant glioma and favor rigorous criteria similar to those in medical oncology, with important modifications. Four response categories are proposed: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD). Response in this scheme is based on major changes in tumor size on the enhanced computed tomographic (CT) or magnetic resonance imaging (MRI) scan. Scan changes are interpreted in light of steroid use and neurologic findings. We advocate careful patient selection, emphasize pitfalls in the assessment of response, and suggest guidelines to minimize misinterpretations of response.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Am. J. Roentgenol.Home page
J. M. Provenzale, C. Ison, and D. DeLong
Bidimensional Measurements in Brain Tumors: Assessment of Interobserver Variability
Am. J. Roentgenol., December 1, 2009; 193(6): W515 - W522.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Ghesquieres, C. Ferlay, C. Sebban, D. Perol, A. Bosly, O. Casasnovas, O. Reman, B. Coiffier, H. Tilly, P. Morel, et al.
Long-term follow-up of an age-adapted C5R protocol followed by radiotherapy in 99 newly diagnosed primary CNS lymphomas: a prospective multicentric phase II study of the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
Ann. Onc., November 18, 2009; (2009) mdp529v2.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
R. M. Green, T. F. Cloughesy, R. Stupp, L. M. DeAngelis, E. A. Woyshner, D. E. Ney, and A. B. Lassman
Bevacizumab for recurrent ependymoma
Neurology, November 17, 2009; 73(20): 1677 - 1680.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Felsberg, M. Rapp, S. Loeser, R. Fimmers, W. Stummer, M. Goeppert, H.-J. Steiger, B. Friedensdorf, G. Reifenberger, and M. C. Sabel
Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients
Clin. Cancer Res., November 1, 2009; 15(21): 6683 - 6693.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. M. Trippett, C. Herzog, J. A. Whitlock, J. Wolff, J. Kuttesch, R. Bagatell, S. P. Hunger, J. Boklan, A. A. Smith, R. J. Arceci, et al.
Phase I and Pharmacokinetic Study of Cetuximab and Irinotecan in Children With Refractory Solid Tumors: A Study of the Pediatric Oncology Experimental Therapeutic Investigators' Consortium
J. Clin. Oncol., October 20, 2009; 27(30): 5102 - 5108.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
F. M. Iwamoto, L. E. Abrey, K. Beal, P. H. Gutin, M. K. Rosenblum, V. E. Reuter, L. M. DeAngelis, and A. B. Lassman
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
Neurology, October 13, 2009; 73(15): 1200 - 1206.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
C Hagen, H D Schroeder, S Hansen, C Hagen, and M Andersen
Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy
Eur. J. Endocrinol., October 1, 2009; 161(4): 631 - 637.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
H. S. Friedman, M. D. Prados, P. Y. Wen, T. Mikkelsen, D. Schiff, L. E. Abrey, W.K. A. Yung, N. Paleologos, M. K. Nicholas, R. Jensen, et al.
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
J. Clin. Oncol., October 1, 2009; 27(28): 4733 - 4740.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
J. H. Sampson, G. E. Archer, D. A. Mitchell, A. B. Heimberger, J. E. Herndon II, D. Lally-Goss, S. McGehee-Norman, A. Paolino, D. A. Reardon, A. H. Friedman, et al.
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
Mol. Cancer Ther., October 1, 2009; 8(10): 2773 - 2779.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
F. ZUSTOVICH, G. LOMBARDI, A. DELLA PUPPA, A. ROTILIO, R. SCIENZA, and D. PASTORELLI
A Phase II Study of Cisplatin and Temozolomide in Heavily Pre-treated Patients with Temozolomide-refractory High-grade Malignant Glioma
Anticancer Res, October 1, 2009; 29(10): 4275 - 4279.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Neyns, J. Sadones, E. Joosens, F. Bouttens, L. Verbeke, J.-F. Baurain, L. D'Hondt, T. Strauven, C. Chaskis, P. In't Veld, et al.
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
Ann. Onc., September 1, 2009; 20(9): 1596 - 1603.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. L. Clarke, F. M. Iwamoto, J. Sul, K. Panageas, A. B. Lassman, L. M. DeAngelis, A. Hormigo, C. P. Nolan, I. Gavrilovic, S. Karimi, et al.
Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma
J. Clin. Oncol., August 10, 2009; 27(23): 3861 - 3867.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Angelov, N. D. Doolittle, D. F. Kraemer, T. Siegal, G. H. Barnett, D. M. Peereboom, G. Stevens, J. McGregor, K. Jahnke, C. A. Lacy, et al.
Blood-Brain Barrier Disruption and Intra-Arterial Methotrexate-Based Therapy for Newly Diagnosed Primary CNS Lymphoma: A Multi-Institutional Experience
J. Clin. Oncol., July 20, 2009; 27(21): 3503 - 3509.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
W. B. Pope, H. J. Kim, J. Huo, J. Alger, M. S. Brown, D. Gjertson, V. Sai, J. R. Young, L. Tekchandani, T. Cloughesy, et al.
Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment
Radiology, July 1, 2009; 252(1): 182 - 189.
[Abstract] [Full Text] [PDF]

Home page
 Anticancer ResHome page
A. FABI, M. RUSSILLO, G. METRO, A. VIDIRI, S. DI GIOVANNI, and F. COGNETTI
Pseudoprogression and MGMT Status in Glioblastoma Patients: Implications in Clinical Practice
Anticancer Res, July 1, 2009; 29(7): 2607 - 2610.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. van den Bent, M. A. Vogelbaum, P. Y. Wen, D. R. Macdonald, and S. M. Chang
End Point Assessment in Gliomas: Novel Treatments Limit Usefulness of Classical Macdonald's Criteria
J. Clin. Oncol., June 20, 2009; 27(18): 2905 - 2908.
[Full Text] [PDF]

Home page
 The OncologistHome page
A. S. Chi, A. G. Sorensen, R. K. Jain, and T. T. Batchelor
Angiogenesis as a Therapeutic Target in Malignant Gliomas
Oncologist, June 1, 2009; 14(6): 621 - 636.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. N. Kreisl, L. Kim, K. Moore, P. Duic, S. Kotliarova, J. Walling, L. Musib, D. Thornton, P. S. Albert, and H. A. Fine
A Phase I Trial of Enzastaurin in Patients with Recurrent Gliomas
Clin. Cancer Res., May 15, 2009; 15(10): 3617 - 3623.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
S. Taillibert, L. A. Vincent, B. Granger, Y. Marie, C. Carpentier, R. Guillevin, A. Bellanger, K. Mokhtari, A. Rousseau, D. Psimaras, et al.
Bevacizumab and irinotecan for recurrent oligodendroglial tumors
Neurology, May 5, 2009; 72(18): 1601 - 1606.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. Stupp, F. Roila, and On behalf of the ESMO Guidelines Working Group
Malignant glioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc., May 1, 2009; 20(suppl_4): iv126 - iv128.
[Full Text] [PDF]

Home page
 JCOHome page
E. Galanis, K. A. Jaeckle, M. J. Maurer, J. M. Reid, M. M. Ames, J. S. Hardwick, J. F. Reilly, A. Loboda, M. Nebozhyn, V. R. Fantin, et al.
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
J. Clin. Oncol., April 20, 2009; 27(12): 2052 - 2058.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Glas, C. Happold, J. Rieger, D. Wiewrodt, O. Bahr, J. P. Steinbach, W. Wick, R.-D. Kortmann, G. Reifenberger, M. Weller, et al.
Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide
J. Clin. Oncol., March 10, 2009; 27(8): 1257 - 1261.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Brandes, A. Tosoni, E. Franceschi, G. Sotti, G. Frezza, P. Amista, L. Morandi, F. Spagnolli, and M. Ermani
Recurrence Pattern After Temozolomide Concomitant With and Adjuvant to Radiotherapy in Newly Diagnosed Patients With Glioblastoma: Correlation With MGMT Promoter Methylation Status
J. Clin. Oncol., March 10, 2009; 27(8): 1275 - 1279.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. van den Bent, A. A. Brandes, R. Rampling, M. C.M. Kouwenhoven, J. M. Kros, A. F. Carpentier, P. M. Clement, M. Frenay, M. Campone, J.-F. Baurain, et al.
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
J. Clin. Oncol., March 10, 2009; 27(8): 1268 - 1274.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. A. Quinn, S. X. Jiang, D. A. Reardon, A. Desjardins, J. J. Vredenburgh, J. N. Rich, S. Gururangan, A. H. Friedman, D. D. Bigner, J. H. Sampson, et al.
Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma
J. Clin. Oncol., March 10, 2009; 27(8): 1262 - 1267.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. C. Chamberlain, M. M. Mrugala, A. D. Norden, G. S. Young, and P. Y. Wen
BEVACIZUMAB FOR RECURRENT MALIGNANT GLIOMAS: EFFICACY, TOXICITY, AND PATTERNS OF RECURRENCE
Neurology, February 24, 2009; 72(8): 772 - 774.
[Full Text] [PDF]

Home page
 JCOHome page
T. N. Kreisl, L. Kim, K. Moore, P. Duic, C. Royce, I. Stroud, N. Garren, M. Mackey, J. A. Butman, K. Camphausen, et al.
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
J. Clin. Oncol., February 10, 2009; 27(5): 740 - 745.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
R. Liu, K. Solheim, M.-Y. Polley, K. R. Lamborn, M. Page, A. Fedoroff, J. Rabbitt, N. Butowski, M. Prados, and S. M. Chang
Quality of life in low-grade glioma patients receiving temozolomide
Neuro-oncol, January 1, 2009; 11(1): 59 - 68.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
M. A. Vogelbaum, B. Berkey, D. Peereboom, D. Macdonald, C. Giannini, J. H. Suh, R. Jenkins, J. Herman, P. Brown, D. T. Blumenthal, et al.
Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131
Neuro-oncol, January 1, 2009; 11(2): 167 - 175.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
K. Jahnke, L. L. Muldoon, C. G. Varallyay, S. J. Lewin, R. D. Brown, D. F. Kraemer, C. Soussain, and E. A. Neuwelt
Efficacy and MRI of rituximab and methotrexate treatment in a nude rat model of CNS lymphoma
Neuro-oncol, January 1, 2009; 11(5): 503 - 513.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
J. A. Quinn, S. X. Jiang, D. A. Reardon, A. Desjardins, J. J. Vredenburgh, J. N. Rich, S. Gururangan, A. H. Friedman, D. D. Bigner, J. H. Sampson, et al.
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant glioma
Neuro-oncol, January 1, 2009; 11(5): 556 - 561.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
E. C. Quant, A. D. Norden, J. Drappatz, A. Muzikansky, L. Doherty, D. LaFrankie, A. Ciampa, S. Kesari, and P. Y. Wen
Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab
Neuro-oncol, January 1, 2009; 11(5): 550 - 555.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Kesari, D. Schiff, J. Drappatz, D. LaFrankie, L. Doherty, E. A. Macklin, A. Muzikansky, S. Santagata, K. L. Ligon, A. D. Norden, et al.
Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults
Clin. Cancer Res., January 1, 2009; 15(1): 330 - 337.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
S. M. Chang, J. Clarke, and P. Wen
Novel Imaging Response Assessment for Drug Therapies in Recurrent Malignant Glioma
ASCO Educational Book, January 1, 2009; 2009(1): 107 - 111.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
P. Y. Wen, A. D. Norden, and J. Drappatz
Antiangiogenic Therapies for Malignant Gliomas
ASCO Educational Book, January 1, 2009; 2009(1): 113 - 117.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Pallini, L. Ricci-Vitiani, G. L. Banna, M. Signore, D. Lombardi, M. Todaro, G. Stassi, M. Martini, G. Maira, L. M. Larocca, et al.
Cancer Stem Cell Analysis and Clinical Outcome in Patients with Glioblastoma Multiforme
Clin. Cancer Res., December 15, 2008; 14(24): 8205 - 8212.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Reardon, K. L. Fink, T. Mikkelsen, T. F. Cloughesy, A. O'Neill, S. Plotkin, M. Glantz, P. Ravin, J. J. Raizer, K. M. Rich, et al.
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
J. Clin. Oncol., December 1, 2008; 26(34): 5610 - 5617.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Desjardins, D. A. Reardon, J. E. Herndon II, J. Marcello, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, J. Sampson, L. Bailey, et al.
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Clin. Cancer Res., November 1, 2008; 14(21): 7068 - 7073.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Raymond, A. A. Brandes, C. Dittrich, P. Fumoleau, B. Coudert, P. M.J. Clement, M. Frenay, R. Rampling, R. Stupp, J. M. Kros, et al.
Phase II Study of Imatinib in Patients With Recurrent Gliomas of Various Histologies: A European Organisation for Research and Treatment of Cancer Brain Tumor Group Study
J. Clin. Oncol., October 1, 2008; 26(28): 4659 - 4665.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. N. Haining, J. Davies, H. Kanzler, L. Drury, T. Brenn, J. Evans, J. Angelosanto, S. Rivoli, K. Russell, S. George, et al.
CpG Oligodeoxynucleotides Alter Lymphocyte and Dendritic Cell Trafficking in Humans
Clin. Cancer Res., September 1, 2008; 14(17): 5626 - 5634.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Hamstra, C. J. Galban, C. R. Meyer, T. D. Johnson, P. C. Sundgren, C. Tsien, T. S. Lawrence, L. Junck, D. J. Ross, A. Rehemtulla, et al.
Functional Diffusion Map As an Early Imaging Biomarker for High-Grade Glioma: Correlation With Conventional Radiologic Response and Overall Survival
J. Clin. Oncol., July 10, 2008; 26(20): 3387 - 3394.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. De Vleeschouwer, S. Fieuws, S. Rutkowski, F. Van Calenbergh, J. Van Loon, J. Goffin, R. Sciot, G. Wilms, P. Demaerel, M. Warmuth-Metz, et al.
Postoperative Adjuvant Dendritic Cell-Based Immunotherapy in Patients with Relapsed Glioblastoma Multiforme
Clin. Cancer Res., May 15, 2008; 14(10): 3098 - 3104.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Brandes, E. Franceschi, A. Tosoni, V. Blatt, A. Pession, G. Tallini, R. Bertorelle, S. Bartolini, F. Calbucci, A. Andreoli, et al.
MGMT Promoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients
J. Clin. Oncol., May 1, 2008; 26(13): 2192 - 2197.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. M. Spence, M. Muzi, K. R. Swanson, F. O'Sullivan, J. K. Rockhill, J. G. Rajendran, T. C.H. Adamsen, J. M. Link, P. E. Swanson, K. J. Yagle, et al.
Regional Hypoxia in Glioblastoma Multiforme Quantified with [18F]Fluoromisonidazole Positron Emission Tomography before Radiotherapy: Correlation with Time to Progression and Survival
Clin. Cancer Res., May 1, 2008; 14(9): 2623 - 2630.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
V. K. Puduvalli, P. Giglio, M. D. Groves, K. R. Hess, M. R. Gilbert, S. Mahankali, E. F. Jackson, V. A. Levin, C. A. Conrad, S. H. Hsu, et al.
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme
Neuro-oncol, April 1, 2008; 10(2): 216 - 222.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
K. R. Lamborn, W. K. A. Yung, S. M. Chang, P. Y. Wen, T. F. Cloughesy, L. M. DeAngelis, H. I. Robins, F. S. Lieberman, H. A. Fine, K. L. Fink, et al.
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Neuro-oncol, April 1, 2008; 10(2): 162 - 170.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
A. D. Norden, G. S. Young, K. Setayesh, A. Muzikansky, R. Klufas, G. L. Ross, A. S. Ciampa, L. G. Ebbeling, B. Levy, J. Drappatz, et al.
Bevacizumab for recurrent malignant gliomas: Efficacy, toxicity, and patterns of recurrence
Neurology, March 4, 2008; 70(10): 779 - 787.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
J.W. Henson, S. Ulmer, and G.J. Harris
Brain Tumor Imaging in Clinical Trials
AJNR Am. J. Neuroradiol., March 1, 2008; 29(3): 419 - 424.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Brandes, E. Franceschi, A. Tosoni, M. E. Hegi, and R. Stupp
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
Clin. Cancer Res., February 15, 2008; 14(4): 957 - 960.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Gururangan, C. D. Turner, C. F. Stewart, M. O'Shaughnessy, M. Kocak, T. Y. Poussaint, P. C. Phillips, S. Goldman, R. Packer, I. F. Pollack, et al.
Phase I Trial of VNP40101M (Cloretazine) in Children with Recurrent Brain Tumors: A Pediatric Brain Tumor Consortium Study
Clin. Cancer Res., February 15, 2008; 14(4): 1124 - 1130.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
G. Filippini, C. Falcone, A. Boiardi, G. Broggi, M. G. Bruzzone, D. Caldiroli, R. Farina, M. Farinotti, L. Fariselli, G. Finocchiaro, et al.
Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma
Neuro-oncol, February 1, 2008; 10(1): 79 - 87.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Sathornsumetee, Y. Cao, J. E. Marcello, J. E. Herndon II, R. E. McLendon, A. Desjardins, H. S. Friedman, M. W. Dewhirst, J. J. Vredenburgh, and J. N. Rich
Tumor Angiogenic and Hypoxic Profiles Predict Radiographic Response and Survival in Malignant Astrocytoma Patients Treated With Bevacizumab and Irinotecan
J. Clin. Oncol., January 10, 2008; 26(2): 271 - 278.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
A. A. Brandes, A. Tosoni, F. Spagnolli, G. Frezza, M. Leonardi, F. Calbucci, and E. Franceschi
Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: Pitfalls in neurooncology
Neuro-oncol, January 1, 2008; 10(3): 361 - 367.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
J. H. Sampson, G. Akabani, G. E. Archer, M. S. Berger, R. E. Coleman, A. H. Friedman, H. S. Friedman, K. Greer, J. E. Herndon II, S. Kunwar, et al.
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors
Neuro-oncol, January 1, 2008; 10(3): 320 - 329.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
S. Kesari, D. Schiff, J. W. Henson, A. Muzikansky, D. C. Gigas, L. Doherty, T. T. Batchelor, J. A. Longtine, K. L. Ligon, S. Weaver, et al.
Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults
Neuro-oncol, January 1, 2008; 10(3): 300 - 308.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
W. Wick, R. Stupp, A.-C. Beule, J. Bromberg, A. Wick, U. Ernemann, M. Platten, C. Marosi, W. P. Mason, M. van den Bent, et al.
A novel tool to analyze MRI recurrence patterns in glioblastoma
Neuro-oncol, January 1, 2008; 10(6): 1019 - 1024.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
M. Nagane, K. Kobayashi, A. Ohnishi, S. Shimizu, and Y. Shiokawa
Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Protein Expression in Patients with Recurrent Glioblastoma Treated with Temozolomide
Jpn. J. Clin. Oncol., December 21, 2007; (2007) hym132v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. T. Wong and S. Brem
Taming Glioblastoma: Targeting Angiogenesis
J. Clin. Oncol., October 20, 2007; 25(30): 4705 - 4706.
[Full Text] [PDF]

Home page
 JCOHome page
W. Chen, S. Delaloye, D. H.S. Silverman, C. Geist, J. Czernin, J. Sayre, N. Satyamurthy, W. Pope, A. Lai, M. E. Phelps, et al.
Predicting Treatment Response of Malignant Gliomas to Bevacizumab and Irinotecan by Imaging Proliferation With [18F] Fluorothymidine Positron Emission Tomography: A Pilot Study
J. Clin. Oncol., October 20, 2007; 25(30): 4714 - 4721.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. J. Vredenburgh, A. Desjardins, J. E. Herndon II, J. Marcello, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, J. Sampson, et al.
Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme
J. Clin. Oncol., October 20, 2007; 25(30): 4722 - 4729.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. Schiff, P. D. Brown, and C. Giannini
Outcome in adult low-grade glioma: The impact of prognostic factors and treatment
Neurology, September 25, 2007; 69(13): 1366 - 1373.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Wick, J. Felsberg, J. P. Steinbach, U. Herrlinger, M. Platten, B. Blaschke, R. Meyermann, G. Reifenberger, M. Weller, and W. Wick
Efficacy and Tolerability of Temozolomide in an Alternating Weekly Regimen in Patients With Recurrent Glioma
J. Clin. Oncol., August 1, 2007; 25(22): 3357 - 3361.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
S. Kesari, D. Schiff, L. Doherty, D. C. Gigas, T. T. Batchelor, A. Muzikansky, A. O'Neill, J. Drappatz, A. S. Chen-Plotkin, N. Ramakrishna, et al.
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
Neuro-oncol, July 1, 2007; 9(3): 354 - 363.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
A. M.P. Omuro, S. Faivre, and E. Raymond
Lessons learned in the development of targeted therapy for malignant gliomas
Mol. Cancer Ther., July 1, 2007; 6(7): 1909 - 1919.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
E. D. Kirson, V. Dbaly, F. Tovarys, J. Vymazal, J. F. Soustiel, A. Itzhaki, D. Mordechovich, S. Steinberg-Shapira, Z. Gurvich, R. Schneiderman, et al.
Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors
PNAS, June 12, 2007; 104(24): 10152 - 10157.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Eoli, F. Menghi, M. G. Bruzzone, T. De Simone, L. Valletta, B. Pollo, L. Bissola, A. Silvani, D. Bianchessi, L. D'Incerti, et al.
Methylation of O6-Methylguanine DNA Methyltransferase and Loss of Heterozygosity on 19q and/or 17p Are Overlapping Features of Secondary Glioblastomas with Prolonged Survival
Clin. Cancer Res., May 1, 2007; 13(9): 2606 - 2613.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. L. Chinot, M. Barrie, S. Fuentes, N. Eudes, S. Lancelot, P. Metellus, X. Muracciole, D. Braguer, L. Ouafik, P.-M. Martin, et al.
Correlation Between O6-Methylguanine-DNA Methyltransferase and Survival in Inoperable Newly Diagnosed Glioblastoma Patients Treated With Neoadjuvant Temozolomide
J. Clin. Oncol., April 20, 2007; 25(12): 1470 - 1475.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. J. Vredenburgh, A. Desjardins, J. E. Herndon II, J. M. Dowell, D. A. Reardon, J. A. Quinn, J. N. Rich, S. Sathornsumetee, S. Gururangan, M. Wagner, et al.
Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma
Clin. Cancer Res., February 15, 2007; 13(4): 1253 - 1259.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
M. A. Badruddoja, K. Penne, A. Desjardins, D. A. Reardon, J. N. Rich, J. A. Quinn, S. Sathornsumetee, A. H. Friedman, D. D. Bigner, J. E. Herndon II, et al.
Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme
Neuro-oncol, January 1, 2007; 9(1): 70 - 74.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Brandes, A. Tosoni, G. Cavallo, M. Reni, E. Franceschi, L. Bonaldi, R. Bertorelle, M. Gardiman, C. Ghimenton, P. Iuzzolino, et al.
Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study
J. Clin. Oncol., October 10, 2006; 24(29): 4746 - 4753.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
U. Herrlinger, J. Rieger, D. Koch, S. Loeser, B. Blaschke, R.-D. Kortmann, J. P. Steinbach, T. Hundsberger, W. Wick, R. Meyermann, et al.
Phase II Trial of Lomustine Plus Temozolomide Chemotherapy in Addition to Radiotherapy in Newly Diagnosed Glioblastoma: UKT-03
J. Clin. Oncol., September 20, 2006; 24(27): 4412 - 4417.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Illerhaus, R. Marks, G. Ihorst, R. Guttenberger, C. Ostertag, G. Derigs, N. Frickhofen, F. Feuerhake, B. Volk, and J. Finke
High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS Lymphoma
J. Clin. Oncol., August 20, 2006; 24(24): 3865 - 3870.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Y. Wen, W.K. A. Yung, K. R. Lamborn, P. L. Dahia, Y. Wang, B. Peng, L. E. Abrey, J. Raizer, T. F. Cloughesy, K. Fink, et al.
Phase I/II Study of Imatinib Mesylate for Recurrent Malignant Gliomas: North American Brain Tumor Consortium Study 99-08.
Clin. Cancer Res., August 15, 2006; 12(16): 4899 - 4907.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
L. Doherty, D. C. Gigas, S. Kesari, J. Drappatz, R. Kim, J. Zimmerman, L. Ostrowsky, and P. Y. Wen
Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas.
Neurology, July 11, 2006; 67(1): 156 - 158.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. C. Jaffe
Measures of Response: RECIST, WHO, and New Alternatives
J. Clin. Oncol., July 10, 2006; 24(20): 3245 - 3251.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
A. A. Brandes, L. Nicolardi, A. Tosoni, M. Gardiman, P. Iuzzolino, C. Ghimenton, M. Reni, A. Rotilio, G. Sotti, and M. Ermani
Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma
Neuro-oncol, July 1, 2006; 8(3): 253 - 260.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Cairncross, B. Berkey, E. Shaw, R. Jenkins, B. Scheithauer, D. Brachman, J. Buckner, K. Fink, L. Souhami, N. Laperierre, et al.
Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
J. Clin. Oncol., June 20, 2006; 24(18): 2707 - 2714.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. van den Bent, A. F. Carpentier, A. A. Brandes, M. Sanson, M. J.B. Taphoorn, H. J.J.A. Bernsen, M. Frenay, C. C. Tijssen, W. Grisold, L. Sipos, et al.
Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
J. Clin. Oncol., June 20, 2006; 24(18): 2715 - 2722.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Kneifel, D. Cordier, S. Good, M. C.S. Ionescu, A. Ghaffari, S. Hofer, M. Kretzschmar, M. Tolnay, C. Apostolidis, B. Waser, et al.
Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P.
Clin. Cancer Res., June 15, 2006; 12(12): 3843 - 3850.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. Walker, B. Haylock, D. Husband, K. A. Joyce, D. Fildes, M. D. Jenkinson, T. Smith, J. Broome, D. G. du Plessis, and P. C. Warnke
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors
Neurology, June 13, 2006; 66(11): 1661 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
E. Galanis, J. C. Buckner, M. J. Maurer, R. Sykora, R. Castillo, K. V. Ballman, B. J. Erickson, and for the North central cancer treatment Group
Validation of neuroradiologic response assessment in gliomas: Measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods
Neuro-oncol, April 1, 2006; 8(2): 156 - 165.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc
Changing paradigms--an update on the multidisciplinary management of malignant glioma.
Oncologist, February 1, 2006; 11(2): 165 - 180.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
G. D. Shah, S. Kesari, R. Xu, T. T. Batchelor, A. M. O'Neill, F. H. Hochberg, B. Levy, J. Bradshaw, and P. Y. Wen
Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas
Neuro-oncol, January 1, 2006; 8(1): 38 - 46.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
A. Carpentier, F. Laigle-Donadey, S. Zohar, L. Capelle, A. Behin, A. Tibi, N. Martin-Duverneuil, M. Sanson, L. Lacomblez, S. Taillibert, et al.
Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
Neuro-oncol, January 1, 2006; 8(1): 60 - 66.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. J. French, S. M.A. Swagemakers, J. H.A. Nagel, M. C.M. Kouwenhoven, E. Brouwer, P. van der Spek, T. M. Luider, J. M. Kros, M. J. van den Bent, and P. A. Sillevis Smitt
Gene Expression Profiles Associated with Treatment Response in Oligodendrogliomas
Cancer Res., December 15, 2005; 65(24): 11335 - 11344.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
D. A. Hamstra, T. L. Chenevert, B. A. Moffat, T. D. Johnson, C. R. Meyer, S. K. Mukherji, D. J. Quint, S. S. Gebarski, X. Fan, C. I. Tsien, et al.
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma
PNAS, November 15, 2005; 102(46): 16759 - 16764.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. B. Lassman, M. R. Rossi, J. R. Razier, L. E. Abrey, F. S. Lieberman, C. N. Grefe, K. Lamborn, W. Pao, A. H. Shih, J. G. Kuhn, et al.
Molecular Study of Malignant Gliomas Treated with Epidermal Growth Factor Receptor Inhibitors: Tissue Analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01
Clin. Cancer Res., November 1, 2005; 11(21): 7841 - 7850.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
W. Kuker, T. Nagele, E. Thiel, M. Weller, and U. Herrlinger
Primary central nervous system lymphomas (PCNSL): MRI response criteria revised
Neurology, October 11, 2005; 65(7): 1129 - 1131.
[Abstract] [Full Text] [PDF]

Home page
 Neuro Oncol DukeHome page
S. M. Chang, S. L. Reynolds, N. Butowski, K. R. Lamborn, J. C. Buckner, R. S. Kaplan, and D. D. Bigner
GNOSIS: Guidelines for neuro-oncology: Standards for investigational studies--reporting of phase 1 and phase 2 clinical trials
Neuro-oncol, October 1, 2005; 7(4): 425 - 434.
[Abstract] [PDF]

Home page
 JCOHome page
E. Galanis, J. C. Buckner, M. J. Maurer, J. I. Kreisberg, K. Ballman, J. Boni, J. M. Peralba, R. B. Jenkins, S. R. Dakhil, R. F. Morton, et al.
Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
J. Clin. Oncol., August 10, 2005; 23(23): 5294 - 5304.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. E. Abrey, T. T. Batchelor, A. J.M. Ferreri, M. Gospodarowicz, E. J. Pulczynski, E. Zucca, J. R. Smith, A. Korfel, C. Soussain, L. M. DeAngelis, et al.
Report of an International Workshop to Standardize Baseline Evaluation and Response Criteria for Primary CNS Lymphoma
J. Clin. Oncol., August 1, 2005; 23(22): 5034 - 5043.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Brell, A. Tortosa, E. Verger, J. M. Gil, N. Vinolas, S. Villa, J. J. Acebes, L. Caral, T. Pujol, I. Ferrer, et al.
Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas
Clin. Cancer Res., July 15, 2005; 11(14): 5167 - 5174.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Barrie, C. Couprie, H. Dufour, D. Figarella-Branger, X. Muracciole, K. Hoang-Xuan, D. Braguer, P. M. Martin, J. C. Peragut, F. Grisoli, et al.
Temozolomide in combination with BCNU before and after radiotherapy in patients with inoperable newly diagnosed glioblastoma multiforme
Ann. Onc., July 1, 2005; 16(7): 1177 - 1184.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
W. Chen, T. Cloughesy, N. Kamdar, N. Satyamurthy, M. Bergsneider, L. Liau, P. Mischel, J. Czernin, M. E. Phelps, and D. H.S. Silverman
Imaging Proliferation in Brain Tumors with 18F-FLT PET: Comparison with 18F-FDG
J. Nucl. Med., June 1, 2005; 46(6): 945 - 952.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Yamanaka, J. Homma, N. Yajima, N. Tsuchiya, M. Sano, T. Kobayashi, S. Yoshida, T. Abe, M. Narita, M. Takahashi, et al.
Clinical Evaluation of Dendritic Cell Vaccination for Patients with Recurrent Glioma: Results of a Clinical Phase I/II Trial
Clin. Cancer Res., June 1, 2005; 11(11): 4160 - 4167.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1990 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online